Usefulness of the PARIS Score to Evaluate the Ischemic-hemorrhagic Net Benefit With Ticagrelor and Prasugrel After an Acute Coronary Syndrome.

Acute Coronary Syndrome / therapy Aged Dose-Response Relationship, Drug Drug Therapy, Combination Europe / epidemiology Female Follow-Up Studies Hemorrhage / epidemiology Humans Incidence Ischemia / epidemiology Male Middle Aged Percutaneous Coronary Intervention Platelet Aggregation Inhibitors / administration & dosage Prasugrel Hydrochloride / administration & dosage Registries Retrospective Studies Risk Assessment / methods Ticagrelor / administration & dosage Treatment Outcome

Acute coronary syndrome Bleeding Hemorragia PARIS score Prasugrel Puntuación PARIS Reinfarction Reinfarto Síndrome coronario agudo Ticagrelor

Journal

Revista espanola de cardiologia (English ed.)

ISSN: 1885-5857

Titre abrégé: Rev Esp Cardiol (Engl Ed)

Pays: Spain

ID NLM: 101587954

Informations de publication

Date de publication:
Mar 2019

Historique:

received: 25 08 2017

accepted: 14 02 2018

pubmed: 22 7 2018

medline: 21 3 2019

entrez: 22 7 2018

Statut: ppublish

Résumé

The PARIS score allows combined stratification of ischemic and hemorrhagic risk in patients with ischemic heart disease treated with coronary stenting and dual antiplatelet therapy (DAPT). Its usefulness in patients with acute coronary syndrome (ACS) treated with ticagrelor or prasugrel is unknown. We investigated this issue in an international registry. Retrospective multicenter study with voluntary participation of 11 centers in 6 European countries. We studied 4310 patients with ACS discharged with DAPT with ticagrelor or prasugrel. Ischemic events were defined as stent thrombosis or spontaneous myocardial infarction, and hemorrhagic events as BARC (Bleeding Academic Research Consortium) type 3 or 5 bleeding. Discrimination and calibration were calculated for both PARIS scores (PARIS During a period of 17.2 ± 8.3 months, there were 80 ischemic events (1.9% per year) and 66 bleeding events (1.6% per year). PARIS In patients with ACS treated with DAPT with ticagrelor or prasugrel, the PARIS model helps to properly evaluate the ischemic-hemorrhagic risk.

Identifiants

DOI: 10.1016/j.rec.2018.06.004 PMID: 30029980

pubmed: 30029980

pii: S1885-5857(18)30222-6

doi: 10.1016/j.rec.2018.06.004

pii:

doi:

Substances chimiques

Platelet Aggregation Inhibitors 0

Prasugrel Hydrochloride G89JQ59I13

Ticagrelor GLH0314RVC

Types de publication

Journal Article Multicenter Study Observational Study

Langues

eng spa

Sous-ensembles de citation

Pagination

215-223